Shares of Entrada Therapeutics (NASDAQ: TRDA) tanked more than 30% in pre-market trading on Tuesday after the U.S. FDA placed a clinical hold on TRDA’s Investigational New Drug Application (IND) for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The biopharma company “plans to share additional updates pending further communications with the Agency.”
TRDA stock has risen by more than 40% in the past year.